Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

Key Inclusion Criteria:

• Diagnosis of neovascular age-related macular degeneration (nAMD) in the study eyewithin 36 months of Visit 1.

• Subfoveal choroidal neovascularization (CNV) secondary to nAMD of any lesion type inthe study eye that shows total lesion area ≤30 mm2, CNV component area of ≥50% ofthe total lesion area, and and CNV must not be associated with subfoveal hemorrhage,subfoveal fibrosis, or subfoveal atrophy.

• Previous treatment in the study eye with between 2 and 4 anti-VEGF intravitrealinjections for nAMD (faricimab, ranibizumab, bevacizumab, brolucizumab, oraflibercept) per standard of care within 6 months of Visit 1.

• History of response to prior intravitreal anti-VEGF treatment in the study eye.

• ETDRS BCVA of between 20 and 80 letters (inclusive) in the study eye.

Key Exclusion Criteria:

• ETDRS BCVA <20 letters in the study eye.

• Central subfield thickness > 400 μm or retinal pigment epithelium detachmentthickness >400 μm on SD-OCT in the study eye.

• Subretinal hemorrhage, fibrosis or atrophy of >50% of the total lesion area and/orthat involves the fovea on fundus fluorescein angiography and/or color fundusphotography in the study eye.

• CNV due to causes other than AMD, such are ocular histoplasmosis, trauma,pathological myopia, angioid streaks, choroidal rupture, or uveitis, in the studyeye.

• Any history of macular pathology unrelated to AMD affecting vision or contributingto the presence of intraretinal or subretinal fluid in the study eye.